Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
Public Health Research Institute, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00195-18. Print 2018 Jun.
infections are increasing worldwide and exhibit greater rates of antifungal resistance than those with other species. DNA mismatch repair (MMR) gene deletions, such as , in resulting in a mutator phenotype have recently been reported to facilitate rapid acquisition of antifungal resistance. This study determined the antifungal susceptibility profiles of 210 isolates in 10 hospitals in India and investigated the impact of novel polymorphisms on mutation potential. No echinocandin- or azole-resistant strains and no mutations in hot spot regions were detected among the isolates, supporting our susceptibility testing results. CLSI antifungal susceptibility data showed that the MICs of anidulafungin (geometric mean [GM], 0.12 μg/ml) and micafungin (GM, 0.01 μg/ml) were lower and below the susceptibility breakpoint compared to that of caspofungin (CAS) (GM, 1.31 μg/ml). Interestingly, 69% of the strains sequenced contained six nonsynonymous mutations in , i.e., V239L and the novel mutations E459K, R847C, Q386K, T772S, and V239/D946E. Functional analysis of mutations revealed that 49% of the tested strains (40/81) contained a partial loss-of-function mutation. The novel substitution Q386K produced higher frequencies of CAS-resistant colonies upon expression in the mutant. However, expression of two other novel alleles, i.e., E459K or R847C, did not confer selection of resistant colonies, confirming that not all mutations in the MMR pathway affect its function or generate a phenotype of resistance to antifungal drugs. The lack of drug resistance prevented any correlations from being drawn with respect to genotype.
世界各地的感染正在增加,并且表现出比其他物种更高的抗真菌耐药率。最近有报道称,DNA 错配修复(MMR)基因缺失,如 ,导致突变体表型,有助于快速获得抗真菌耐药性。本研究确定了印度 10 家医院的 210 株 分离株的抗真菌药敏谱,并研究了新型 多态性对突变潜力的影响。在 分离株中未检测到棘白菌素或唑类耐药株,也未检测到热点区域的 突变,这支持了我们的药敏试验结果。CLSI 抗真菌药敏数据显示,阿尼达fungin(几何平均[GM],0.12 μg/ml)和米卡fungin(GM,0.01 μg/ml)的 MIC 值较低,低于卡泊fungin(CAS)(GM,1.31 μg/ml)的药敏折点。有趣的是,69%的 测序菌株在 中含有六个非同义突变,即 V239L 和新的突变 E459K、R847C、Q386K、T772S 和 V239/D946E。对 突变的功能分析表明,49%的测试菌株(40/81)含有部分功能丧失 突变。新型 取代 Q386K 在 突变体中表达时产生更高频率的 CAS 耐药菌落。然而,表达另外两个新的 等位基因,即 E459K 或 R847C,并没有赋予对 CAS 耐药菌落的选择,这证实了 MMR 途径中的并非所有突变都影响其功能或产生抗真菌药物耐药表型。缺乏耐药性阻止了与 基因型相关的任何相关性。